The Respimat^® Soft Mist™ inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction with and preference for the re-usable device. This 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire. In total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious. This study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.

Plain language summary:

Inhalers are often used to treat patients with chronic obstructive pulmonary disease (COPD). However, there are many available, which can lead to confusion and poor inhaler technique. It is important for a patient to be happy with their inhaler. This study looked at how patients liked the re-usable Respimat® Soft Mist™ inhaler vs. their previous inhaler. It also asked whether they would be willing to continue using the device at the end of the study period.After 4–6 weeks of using the re-usable device, patients reported that they were happy with the inhaler and most would be willing to carry on using it.Overall, these results show that doctors can prescribe Respimat re-usable to patients, even if the patient has not used the inhaler before.

中文翻译：

---

当前用户和切换到该设备的用户对可重复使用的 Respimatt® Soft Mist™ 吸入器的患者看法：一项真实世界的非干预性 COPD 研究

Respimat ^®Soft Mist™ 吸入器 (SMI) 最近得到了改进，可重复使用的设备取代了一次性版本。某些国家目前正在逐步淘汰一次性吸入器。本研究旨在评估患者对可重复使用设备的满意度和偏好。这项为期 4-6 周的多中心、开放标签、前瞻性、真实世界、非干预性研究在六个欧洲国家进行。慢性阻塞性肺疾病患者在 2019 年 10 月至 12 月期间被纳入三个队列：(1) 目前使用可重复使用的 Respimat SMI；(2) 在研究开始时从一次性 Respimat SMI 转换；(3) 对任何 Respimat SMI 都不了解。使用患者满意度和偏好问卷 (PASAPQ) 和易用性问卷对患者进行评估。总共招募了262名患者。在跟进时，平均 PASAPQ 总分为 83.3/100，所有三个患者队列的结果相似。大多数患者对可重复使用的设备“满意”或“非常满意”。愿意继续使用该设备的总分是 87.8/100。总共记录了 13 起不良事件，没有一个被归类为严重事件。这项研究为从业者开始使用 Respimat 可重复使用的患者提供真实世界的证据，而不管患者之前使用该吸入器的经验如何。

普通话总结：

吸入器通常用于治疗慢性阻塞性肺病 (COPD) 患者。但是，有许多可用的方法，这可能会导致混淆和吸入器技术不佳。让患者对他们的吸入器感到满意很重要。本研究着眼于患者对可重复使用的 Respimat® Soft Mist™ 吸入器的喜爱程度与他们之前的吸入器相比。它还询问他们是否愿意在研究期结束时继续使用该设备。使用可重复使用的设备 4-6 周后，患者报告他们对吸入器感到满意，大多数人愿意携带总体而言，这些结果表明，即使患者以前没有使用过吸入器，医生也可以为患者开出可重复使用的 Respimat。